Ocular Therapeutix(TM) Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI(TM) in NPDR
(NasdaqGM:OCUL), First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, complementary superiority trials using a novel ordinal diabetic retinopathy severity scale (DRSS) primary endpoint Targeting a broad diabetic retinopathy (DR) label by including patients with non-center-involved diabetic macular […]